The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift
Open accessAbstract
An increasing number of studies clearly demonstrate that coronary microvascular dysfunction (CMD) plays a pivotal role in several cardiovascular diseases.1 In particular, emerging evidence suggests that CMD is the main contributor to myocardial ischaemia in a large subset of patients with chronic stable angina. Indeed, non-obstructive coronary atherosclerosis is observed in up to 50% of patients with angina and positive stress test results undergoing diagnostic coronary angiography.2 Thus, the prevalence of microvascular angina (MVA) is higher than previously thought and associated with worse clinical outcomes than those observed in asymptomatic subjects with similar risk factor burden.3 The diagnosis of MVA is based on the following criteria: (i) symptoms of myocardial ischaemia; (ii) absence of obstructive epicardial coronary artery disease; (iii) evidence of myocardial ischaemia on non-invasive stress testing; and (iv) evidence of impaired coronary microvascular function. The clinical relevance of MVA has historically been overlooked since the diagnostic tools required for the evaluation of the coronary microcirculation are infrequently utilized. A parallel ‘tale’ could be proposed for heart failure (HF) with preserved ejection fraction (HFpEF). Indeed, HFpEF is observed in about 50% of patients presenting with HF symptoms and is characterized by the absence of a relevant reduction of left ventricular ejection fraction (LVEF).4 As with MVA, patients with HFpEF have poorer clinical outcomes compared with asymptomatic subjects exhibiting a similar burden of risk factors. The diagnosis of HFpEF is based on the following: (i) symptoms with or without signs of HF; (ii) normal or only mildy reduced LVEF; (iii) elevated levels of natriuretic peptides; (iv) relevant structural heart disease (i.e. left ventricular hypertrophy, left atrial enlargement) and/or diastolic dysfunction. In both MVA and HFpEF, no therapeutic intervention has hitherto been proven to improve patient outcome; similarly, symptomatic treatment is largely empirical. A key shared characteristic of both conditions is the high prevalence of post-menopausal women. This is widely held to be related to sex hormones such as oestrogen, although the molecular effects of oestrogen on endothelial cells, smooth muscle cells and myocytes are incompletely understood. Nevertheless, experimental studies and post-mortem and observational clinical studies suggest the presence of important differences in myocardial remodelling between females and males in response to different types of injures including aging, pressure and volume overload, and myocardial infarction.5 The figure summarizes the common soil hypothesis for microvascular angina (MVA) and heart failure with preserved ejection fraction (HFpEF). The common soil is represented by coronary microvascular dysfunction, which can be caused by traditional risk factors, chronic inflammation and aging while female sex is a predisposing factor. Coronary microvascular dysfunction is determined by a variable combination of endothelial dysfunction, vascular smooth muscle cell hyperreactivity, vascular remodelling, vascular fibrosis, vascular rarefaction, and increased extravascular pressure. Possible modulating factors have been suggested (see text), which may determine an effect in the direction of MVA (mainly characterized by angina and effort-induced ischemia) or, at the other extreme, of HFpEF (characterized by dyspnoea and echocardiographic alterations). Of note, microinfarcts per se can promote myocardial fibrosis leading to HFpEF. Legend: VSMCs = smooth muscle cells. Stereoarteriogram created by Dr William F.M. Fulton, M.D. Thesis (1960), University of Glasgow and provided with permission from Professor Colin Berry, University of Glasgow. Recent studies suggest that CMD might play a key role also in HFpEF. Indeed, endothelial activation/dysfunction reduces nitric oxide (NO) bioavailability, cyclic guanosine monophosphate content, and protein kinase G in adjacent cardiomyocytes.11 These changes are known to favour hypertrophy and fibrosis contributing to diastolic dysfunction. The importance of inflammation for the induction of cardiac fibrosis and vascular rarefaction has been convincingly demonstrated.12 In particular, transforming growth factor (TGF)-β is likely to play a major role in this setting, as suggested by the observation that disruption of TGF-signalling attenuates pressure overload-induced interstitial fibrosis in the heart.13 Furthermore, endothelial dysfunction contributes to cardiac fibrosis via the reduced bioavailability of NO, known to exert direct anti-fibrotic effects involving the cyclic guanosine monophosphate pathway.14 Finally, NO deprivation favours endothelial cell conversion to a mesenchymal cell type that can gives rise to fibroblasts.15 Thus, a cross-talk between the endothelium and the surrounding vascular tissue as well as the myocardium seems to play a key role in the pathoge
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Mohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., & Redfield, M. M. (2015) · Circulation · doi:10.1161/circulationaha.114.009625 · Cited by 874
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Heart Failure With Preserved Ejection Fraction In Perspective
Pfeffer, M. A., Shah, A. M., & Borlaug, B. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313572 · Cited by 837
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases
Del Buono, M. G., Montone, R. A., Camilli, M., Carbone, S., Narula, J., Lavie, C. J., Niccoli, G., & Crea, F. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.042 · Cited by 635
Self-citationCoronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction
Taqueti, V. R., Solomon, S. D., Shah, A. M., Desai, A. S., Groarke, J. D., Osborne, M. T., Hainer, J., Bibbo, C. F., Dorbala, S., Blankstein, R., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx721 · Cited by 579
Metadata
- Authors
- Crea, F., Bairey Merz, C. N., Beltrame, J. F., Kaski, J. C., Ogawa, H., Ong, P., Sechtem, U., Shimokawa, H., Camici, P. G., & On behalf of the Coronary Vasomotion Disorders International Study Group (COVADIS)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-23
- Volume
- 38
- Issue
- 7
- Pages
- ehw461
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2536803389
- Cited by
- 164
- References
- 2
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. https://app.cochat.ai/papers/10.1093/eurheartj/ehw461
- The paper
- Crea, F., Bairey Merz, C. N., Beltrame, J. F., Kaski, J. C., Ogawa, H., Ong, P., Sechtem, U., Shimokawa, H., Camici, P. G., & On behalf of the Coronary Vasomotion Disorders International Study Group (COVADIS). (2016). The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.